Semaglutide pens for weight loss: the clinical evidence and what to expect

What the trial evidence actually measured

The STEP 1 results are often quoted as a headline, but it is worth understanding what the trial was and was not measuring. Participants used the 2.4mg semaglutide pen alongside a reduced-calorie diet and increased activity — semaglutide was not tested as a standalone intervention. The average weight loss of roughly 15% was across the whole group; some lost considerably more, some less. That kind of variability is normal in weight-management research, and a single percentage tells you little about what you personally might experience.

Since STEP 1, the licensed dose range has expanded. The MHRA approved a dedicated single-dose 7.2mg Wegovy pen on 14 April 2026, following data showing average weight loss of around 20.7% over 72 weeks at that higher dose. The approval applies to adults with a BMI of 30 or above; it does not extend to the cardiovascular or lower-BMI indications. A prescriber decides whether the extended dose pathway is appropriate for an individual patient, based on tolerability and response at each earlier stage.

For the broader picture on the Wegovy injection programme and how it compares with other options, our guide to semaglutide injections covers the full licensed context. The trial data is the starting point, not the whole story.

How the pen is actually used each week

Each Wegovy pen is pre-filled and designed for a single weekly injection. You do not draw up a dose or handle a vial, the pen clicks and locks, and the dose is set. Injections go into subcutaneous fat, not muscle: the front of the abdomen (at least a few centimetres from the navel), the outer thigh, or the upper arm are all licensed sites. Rotating the site each week matters more than most people realise. Repeatedly injecting into the same small area can cause lipohypertrophy, a thickening of the fatty tissue that affects how consistently the medicine absorbs.

Timing within the week is flexible. You can take it on any day, at any time of day, with or without food. What does matter is keeping to a once-weekly rhythm. If you miss a dose and your next scheduled injection is more than five days away, the general guidance is to take the missed dose promptly; if it is within five days, skip it and continue your usual schedule. The Patient Information Leaflet that comes with your pen covers this in detail, and your prescriber is the right person to ask if you are unsure. If you want to walk through the full process before your first pen arrives, our page on how to use semaglutide takes you through each step in detail.

Storage is straightforward: refrigerate at 2 to 8°C until you are ready to use the pen. Once in use, check your specific leaflet for the room-temperature window, it varies slightly by pen format and that figure should come from your own PIL, not a general source. Keeping the pen away from direct heat and light protects the medicine's stability.

Side effects that come up most often with semaglutide pens

Gastrointestinal symptoms are the most commonly reported effects: nausea is the one people mention first, followed by constipation, loose stools, indigestion and, for some, vomiting. They tend to be most noticeable in the first week or two after starting, or after a dose increase, then ease as the body settles. The slow titration schedule exists partly to manage this, the lower starting doses are not at a therapeutic level for weight loss; they are there to let your system adjust before the dose moves up.

Two things worth knowing specifically about the pen format: injection-site reactions (redness, mild bruising, itching) are common and usually short-lived; and changing your injection site each week reduces their frequency. Separately, the MHRA's Yellow Card scheme allows any patient or carer to report a suspected side effect directly to the regulator, with a Black Triangle medicine like semaglutide, those reports feed actively into the ongoing safety review, so they genuinely matter.

Pancreatitis is a less common but more serious risk: severe stomach pain that reaches towards the back, with or without vomiting, should be treated as a reason to stop the pen and seek urgent medical attention, not something to wait out. The NHS semaglutide medicines page has a full list of what to watch for and when to call for help; it is worth reading before you start.

Who the semaglutide pen is licensed for, and the private route

The semaglutide pen is licensed in the UK for adults with a BMI of 30 or above, or BMI 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Thresholds are 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance. Semaglutide is not licensed for weight management in people under 18, and it is not recommended during pregnancy, while breastfeeding or if you are trying to conceive.

On the NHS, Wegovy sits under NICE technology appraisal TA875 and is available through specialist weight management services, with criteria that include a maximum two-year treatment period and multidisciplinary support. Waiting lists are often long, and eligibility is strict. The private route (through a regulated online pharmacy) removes the waiting list but requires the same clinical assessment: a qualified prescriber reviews your health history, weight, and any other medicines you take before any prescription is issued.

If you want to understand the wider range of weight-loss injection options, this page on weight-loss injections addresses a common source of confusion around brand names. For those weighing up costs alongside clinical factors, there is a useful breakdown on the weight-loss treatment overview. One thing worth noting about timing: if you are ordering privately, placing your order on a Monday before noon means the prescription review and dispatch can happen the same day, arriving Tuesday, useful to bear in mind around bank holidays or if payday falls mid-week and you want to avoid a gap in treatment.

If you think the semaglutide pen may be appropriate for you, checking your eligibility through a free consultation is the natural next step. A GPhC-registered prescriber, not an automated system, reviews every application.